Global Neuropathy Pain Treatment Market 2024-2028

The neuropathy pain treatment market is forecasted to grow by USD 5840.05 mn during 2023-2028, accelerating at a CAGR of 10.96% during the forecast period. The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the presence of a large patient pool of neuropathy pain, a growing focus on the development of drugs for the treatment of diabetic neuropathy pain, and rising penetration of generic drugs.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	10.11%
CAGR	10.96%
Incremental Value	$5840.05mn

Technavio's neuropathy pain treatment market is segmented as below:

By Indication

Diabetic neuropathy
Chemotherapy-induced neuropathy pain
Postherpetic neuralgia
Others

By Distribution Channel

Retail pharmacies
Hospital pharmacies
Online pharmacies

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the development of topical patches for neuropathy pain treatment changing market dynamics as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years. Also, the growing focus on emerging economies and the association between obesity and endocrine disorders will lead to sizable demand in the market.

The report on the neuropathy pain treatment market covers the following areas:

Neuropathy pain treatment market sizing
Neuropathy pain treatment market forecast
Neuropathy pain treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neuropathy pain treatment market vendors that include Abbott Laboratories, Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, GlaxoSmithKline Plc, Johnson and Johnson, Mallinckrodt Plc, Neuracle Lifesciences Pvt. Ltd., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., and VistaGen Therapeutics Inc.. Also, the neuropathy pain treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR43322

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Indication
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global neuropathy pain treatment market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global neuropathy pain treatment market 2018 - 2022 ($ million)
4.2 Indication Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Indication Segment 2018 - 2022 ($ million)
4.3 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Indication

6.1 Market segments
Exhibit 30: Chart on Indication - Market share 2023-2028 (%)
Exhibit 31: Data Table on Indication - Market share 2023-2028 (%)
6.2 Comparison by Indication
Exhibit 32: Chart on Comparison by Indication
Exhibit 33: Data Table on Comparison by Indication
6.3 Diabetic neuropathy - Market size and forecast 2023-2028
Exhibit 34: Chart on Diabetic neuropathy - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Diabetic neuropathy - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Diabetic neuropathy - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Diabetic neuropathy - Year-over-year growth 2023-2028 (%)
6.4 Chemotherapy-induced neuropathy pain - Market size and forecast 2023-2028
Exhibit 38: Chart on Chemotherapy-induced neuropathy pain - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Chemotherapy-induced neuropathy pain - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Chemotherapy-induced neuropathy pain - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Chemotherapy-induced neuropathy pain - Year-over-year growth 2023-2028 (%)
6.5 Postherpetic neuralgia - Market size and forecast 2023-2028
Exhibit 42: Chart on Postherpetic neuralgia - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Postherpetic neuralgia - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Postherpetic neuralgia - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Postherpetic neuralgia - Year-over-year growth 2023-2028 (%)
6.6 Others - Market size and forecast 2023-2028
Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.7 Market opportunity by Indication
Exhibit 50: Market opportunity by Indication ($ million)
Exhibit 51: Data Table on Market opportunity by Indication ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 54: Chart on Comparison by Distribution Channel
Exhibit 55: Data Table on Comparison by Distribution Channel
7.3 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 56: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
7.4 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 60: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 61: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 62: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 68: Market opportunity by Distribution Channel ($ million)
Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 Canada - Market size and forecast 2023-2028
Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.10 China - Market size and forecast 2023-2028
Exhibit 103: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 104: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 105: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on China - Year-over-year growth 2023-2028 (%)
9.11 UK - Market size and forecast 2023-2028
Exhibit 107: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 108: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 109: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ million)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 119: Abbott Laboratories - Overview
Exhibit 120: Abbott Laboratories - Business segments
Exhibit 121: Abbott Laboratories - Key news
Exhibit 122: Abbott Laboratories - Key offerings
Exhibit 123: Abbott Laboratories - Segment focus
12.4 Astellas Pharma Inc.
Exhibit 124: Astellas Pharma Inc. - Overview
Exhibit 125: Astellas Pharma Inc. - Product / Service
Exhibit 126: Astellas Pharma Inc. - Key news
Exhibit 127: Astellas Pharma Inc. - Key offerings
12.5 AstraZeneca Plc
Exhibit 128: AstraZeneca Plc - Overview
Exhibit 129: AstraZeneca Plc - Product / Service
Exhibit 130: AstraZeneca Plc - Key news
Exhibit 131: AstraZeneca Plc - Key offerings
12.6 Baxter International Inc.
Exhibit 132: Baxter International Inc. - Overview
Exhibit 133: Baxter International Inc. - Business segments
Exhibit 134: Baxter International Inc. - Key news
Exhibit 135: Baxter International Inc. - Key offerings
Exhibit 136: Baxter International Inc. - Segment focus
12.7 Biogen Inc.
Exhibit 137: Biogen Inc. - Overview
Exhibit 138: Biogen Inc. - Product / Service
Exhibit 139: Biogen Inc. - Key offerings
12.8 Bristol Myers Squibb Co.
Exhibit 140: Bristol Myers Squibb Co. - Overview
Exhibit 141: Bristol Myers Squibb Co. - Product / Service
Exhibit 142: Bristol Myers Squibb Co. - Key news
Exhibit 143: Bristol Myers Squibb Co. - Key offerings
12.9 Daiichi Sankyo Co. Ltd.
Exhibit 144: Daiichi Sankyo Co. Ltd. - Overview
Exhibit 145: Daiichi Sankyo Co. Ltd. - Product / Service
Exhibit 146: Daiichi Sankyo Co. Ltd. - Key news
Exhibit 147: Daiichi Sankyo Co. Ltd. - Key offerings
12.10 Dr Reddys Laboratories Ltd.
Exhibit 148: Dr Reddys Laboratories Ltd. - Overview
Exhibit 149: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 150: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 151: Dr Reddys Laboratories Ltd. - Segment focus
12.11 Eli Lilly and Co.
Exhibit 152: Eli Lilly and Co. - Overview
Exhibit 153: Eli Lilly and Co. - Product / Service
Exhibit 154: Eli Lilly and Co. - Key news
Exhibit 155: Eli Lilly and Co. - Key offerings
12.12 Endo International Plc
Exhibit 156: Endo International Plc - Overview
Exhibit 157: Endo International Plc - Business segments
Exhibit 158: Endo International Plc - Key news
Exhibit 159: Endo International Plc - Key offerings
Exhibit 160: Endo International Plc - Segment focus
12.13 Johnson and Johnson
Exhibit 161: Johnson and Johnson - Overview
Exhibit 162: Johnson and Johnson - Business segments
Exhibit 163: Johnson and Johnson - Key news
Exhibit 164: Johnson and Johnson - Key offerings
Exhibit 165: Johnson and Johnson - Segment focus
12.14 Pfizer Inc.
Exhibit 166: Pfizer Inc. - Overview
Exhibit 167: Pfizer Inc. - Product / Service
Exhibit 168: Pfizer Inc. - Key news
Exhibit 169: Pfizer Inc. - Key offerings
12.15 Sanofi
Exhibit 170: Sanofi - Overview
Exhibit 171: Sanofi - Business segments
Exhibit 172: Sanofi - Key news
Exhibit 173: Sanofi - Key offerings
Exhibit 174: Sanofi - Segment focus
12.16 Sun Pharmaceutical Industries Ltd.
Exhibit 175: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 176: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 177: Sun Pharmaceutical Industries Ltd. - Key offerings
12.17 VistaGen Therapeutics Inc.
Exhibit 178: VistaGen Therapeutics Inc. - Overview
Exhibit 179: VistaGen Therapeutics Inc. - Product / Service
Exhibit 180: VistaGen Therapeutics Inc. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 181: Inclusions checklist
Exhibit 182: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 183: Currency conversion rates for US$
13.4 Research methodology
Exhibit 184: Research methodology
Exhibit 185: Validation techniques employed for market sizing
Exhibit 186: Information sources
13.5 List of abbreviations
Exhibit 187: List of abbreviations